Puriblood Medical Co., Ltd. (TPEX:6847)
Taiwan · Delayed Price · Currency is TWD 49.90
+0.05 (0.10%)
At close: Apr 24, 2026
Puriblood Medical Revenue
Puriblood Medical had revenue of 40.25M TWD in the half year ending June 30, 2025, with 24.67% growth. This brings the company's revenue in the last twelve months to 117.35M, down -7.28% year-over-year. In the year 2024, Puriblood Medical had annual revenue of 110.67M, down -11.65%.
Revenue (ttm)
117.35M
Revenue Growth
-7.28%
P/S Ratio
6.05
Revenue / Employee
2.67M
Employees
44
Market Cap
710.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 110.67M | -14.60M | -11.65% |
| Dec 31, 2023 | 125.27M | -12.17M | -8.86% |
| Dec 31, 2022 | 137.44M | 82.86M | 151.79% |
| Dec 31, 2021 | 54.59M | 15.94M | 41.25% |
| Dec 31, 2020 | 38.65M | 35.55M | 1,149.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 20.51B |
| PharmaEssentia | 15.63B |
| Sofiva Genomics | 385.71M |
| BioLASCO Taiwan | 262.66M |
| Bioray Biotech | 230.06M |
| Vectorite Biomedical | 67.90M |
| Caliway Biopharmaceuticals | 38.04M |
| AmCad BioMed | 30.44M |